Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with psoriatic arthritis by a rheumatologist, using a recognised set of classification criteria called CASPAR
- People who are starting a medication called guselkumab as their first, second, third, or fourth targeted treatment for psoriatic arthritis as part of their normal medical care
- People whose rheumatologist has decided to prescribe guselkumab in line with the approved prescribing guidelines for this medication
- People whose rheumatologist made the decision to prescribe guselkumab before and separately from any decision about joining this study, based on standard clinical care
- People who have been given information about the study, have verbally agreed to take part, and have not objected to their data being collected, in line with French regulations
Who may not be able to join:
- People who have previously taken a type of medication known as an interleukin-23 inhibitor (IL-23i) (confirm with trial site)
- People who are already taking two or more targeted therapies for psoriatic arthritis or psoriasis at the same time, such as biologics, JAK inhibitors, or PDE4 inhibitors
- People for whom guselkumab is medically unsuitable according to its approved prescribing guidelines — for example, those with a known allergy to guselkumab or an active serious infection such as active tuberculosis
- People who are unwilling or unable to have their health information collected over a long period of time
- People who have taken part in a trial of an unapproved drug, vaccine, or medical device within the 30 days before joining this study
- People who are currently enrolled in another interventional study or in an observational study sponsored by Janssen-Cilag France
- People who are subject to a legal guardianship arrangement, court-ordered protection, or a similar formal legal measure relating to their personal decision-making (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen-Cilag France Clinical Trial, Janssen-Cilag France
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of Participants Still Receiving Treatment at 1 Year; Percentage of Participants Still Receiving Treatment at Persistence Time; Number of Participants Starting New Treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.